Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (科济药业-B) shares rose over 9% following the announcement of positive results from a clinical trial for its CAR-T cell therapy targeting pancreatic cancer, which was presented at the ESMO annual meeting [1] Group 1: Clinical Trial Results - Kintor's CAR-T cell product, CT053 (赛恺泽), is undergoing an Ib phase registration clinical trial in China for adjuvant therapy in pancreatic cancer [1] - This trial is the first global study exploring CAR-T cell therapy for adjuvant treatment in solid tumors [1] Group 2: Regulatory Developments - On September 20, the National Healthcare Security Administration (国家医保局) announced the completion of expert review for the first version of the commercial insurance innovative drug catalog [1] - Kintor's CT053, along with four other CAR-T drugs, passed the expert review and is expected to be included in this year's basic medical insurance catalog and commercial insurance innovative drug catalog [1]
科济药业-B早盘涨超9% 公司在2025年ESMO年会上呈列泽沃基奥仑赛注射液研究成果